GnRH receptor

BIM 21009 is a potent LHRH/GnRH receptor antagonist, primarily targeting the gonadotropin-releasing hormone pathway. It demonstrates significant inhibitory effects on tumor growth, making it an essential tool for research in oncology and reproductive biology. BIM 21009 is valuable for studies focused on hormone-dependent cancers and the modulation of reproductive functions.

Antide acetate is a potent LHRH (luteinizing hormone-releasing hormone) antagonist that effectively modulates hormonal signaling pathways. This compound is primarily utilized in research applications focused on prostate cancer, where it plays a critical role in studying hormone-driven tumor progression and potential therapeutic interventions.

T-98475 is a potent, orally active, non-peptide luteinizing hormone-releasing hormone (LHRH) receptor antagonist, exhibiting an IC50 of 0.2 nM. This compound effectively inhibits LHRH signaling, making it a valuable tool for studies related to reproductive endocrinology and hormone regulation. It is suitable for investigating the role of LHRH in various physiological and pathological conditions, including hormone-responsive cancers and infertility research.

Opigolix is a GnRH receptor antagonist that plays a crucial role in the modulation of gonadotropin release. This compound exhibits significant biological activity in the context of hormonal regulation, making it a valuable tool for research applications related to endometriosis and rheumatoid arthritis. Its mechanism of action involves the inhibition of GnRH signaling pathways, thereby influencing reproductive hormone levels and related physiological processes.